Nuvectis Pharma (NVCT) Retained Earnings (2021 - 2026)

Nuvectis Pharma has reported Retained Earnings for 6 years, with the latest figure at -$105.7 million in Q1 2026.

• Quarterly Retained Earnings fell 34.52% year-over-year to -$105.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$105.7 million (down 34.52% YoY) and the FY2025 annual result came in at $118.1 million, up 261.24% from the prior year.
• Retained Earnings declined to -$105.7 million in Q1 2026 per NVCT's latest filing, from $118.1 million in the prior quarter.
• Over five years, Retained Earnings peaked at $118.1 million in Q4 2025 and troughed at -$105.7 million in Q1 2026.
• A 5-year average of -$27.3 million and a median of -$41.7 million in 2023 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2022 and 2024: Retained Earnings slumped 1790.54% in 2022, then jumped 301.22% in 2024.
• Over 5 years, Retained Earnings stood at -$32.0 million in 2022, then sank by 69.6% to -$54.2 million in 2023, then plunged by 35.03% to -$73.2 million in 2024, then surged by 261.24% to $118.1 million in 2025, then plunged by 189.5% to -$105.7 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$105.7 million, $118.1 million, and -$92.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.